Physician-Patient Alliance for Health and Safety Grants CME Accreditation to First Wave of 2024 World Sepsis Spotlight Courses
11 juin 2024 10h00 HE
|
The Physician-Patient Alliance for Health & Safety
Physician-Patient Alliance for Health & Safety accredits first 4 sessions from the World Sepsis Spotlight: Unmet Needs in Sepsis Diagnosis and Treatment.
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
03 juin 2024 08h14 HE
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
deepull appoints Didier Deltort to its Board of Directors
22 mai 2024 03h00 HE
|
DeepUll
deepull appoints Didier Deltort to its Board of Directors Barcelona, Spain – 22 May 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen...
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
25 avr. 2024 03h00 HE
|
DeepUll
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024 UllCORE is designed to transform life-saving clinical decision making for sepsis...
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer
18 avr. 2024 02h00 HE
|
DeepUll
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer Kimberle Chapin brings significant expertise in microbiology and infectious...
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
11 avr. 2024 08h05 HE
|
Enlivex Therapeutics Ltd
Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes...
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
10 avr. 2024 08h00 HE
|
Adrenomed AG
With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths...
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
27 févr. 2024 15h52 HE
|
BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment
12 févr. 2024 08h30 HE
|
HelixBind
Study shows RaPID/BSI assay can accurately identify bloodstream infections associated with sepsis in patients undergoing antimicrobial treatment.
Pancreatic Stone Protein Testing Market revenue to reach USD 5 Billion by 2033, says Research Nester
07 févr. 2024 07h30 HE
|
Research Nester
New York, Feb. 07, 2024 (GLOBE NEWSWIRE) -- The global pancreatic stone protein testing market size is predicted to grow at a CAGR of over ~3% from 2023 to 2033. The market is projected to garner a...